The cost effectiveness of pneumococcal conjugate vaccine in the routine infant immunisation programme of The Gambia

Journal of Pharmaceutical Health Services Research

Volumn 2, Issue 3, 2011, Pages 175-184

  Touray, Morro M L ^a   Hutubessy, Raymond ^c   Acharya, Arnab ^b  

^a UNIVERSITY OF GLAMORGAN   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cost effectiveness; Developing countries; Economic evaluations; Low and middle income countries; Pneumococcal conjugate vaccine; The Gambia

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; CHILD DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG USE; GAMBIA; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; INFANT; MASS IMMUNIZATION; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 80051811740     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00057.x     Document Type: Article

References (44)

1. World Health Organization. Weekly Epidemiological Record. Geneva: World Health Organization, 2007.
2. O'Dempsey TJ. Pneumococcal disease among children in a rural area of West Africa. Pediatr Infect Dis J 1996; 15: 431-437.
3. Wardlaw T etal. Pneumonia the Forgotten Killer of Children. Geneva: UNICEF and World Health Organization, 2006.
4. Greenwood BM etal. Deaths in infancy and early childhood in a well vaccinated rural West African population. Ann Trop Paediatr 1987; 7: 91-99.
5. WHO. Guidelines for Estimating Costs of Introducing New Vaccines into the National Immunisation System. Geneva: World Health Organization, 2002.
6. Cutts F etal. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365: 1139-1146.
7. Ministry of Health and Social Welfare. National Health Policy of The Gambia - Health Is Wealth (2007-2020). Banjul: Ministry of Health and Social Welfare, 2007.
8. Gold MR etal. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
9. Tan Torres Edejer T etal. Making Choices in Health: WHO Guide to Cost Effectiveness. Geneva: World Health Organization, 2003: 318.
10. Drummond MF etal. Methods for the Economic Evaluation of Healthcare Programmes, 3rd edn. Oxford: Oxford University Press, 2005: 396.
11. World Health Organization. Guide on Standardisation of Economic Evaluations of Immunisation Programmes. Vol. WHO/IVB/08.14. Geneva: World Health Organization, 2008.
12. Gold MR etal. Cost-Effectiveness in Health and Medicine. Vol. 315. New York: Oxford University Press, 1996.
13. Iinternational Monetary Fund. World Economic Outlook Database. Washington (DC): International Monetary Fund, 2006.
14. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization Commission on Macroeconomics and Health, 2001.
15. Global Alliance for Vaccines and Immunization. Advance Market Commitments (AMCs). (accessed 20 February 2007).
16. World Health Organization. Choosing Interventions that are Cost Effective. (accessed 26 August 2006). WHO, c2005.
17. World Health Organization. The GAVI financial sustainability planning process. Immunization financing 2010. (accessed 20 July 2010).
18. Fryer JE. International Drug Price Indicator Guide. Management Science for Health. 2006. (accessed 15 October 2006).
19. World Health Organization. WHO country co-operation strategy. The Republic of The Gambia 2002-2005 2002.
20. World Health Organization. WHO and UNICEF Review of National Immunisation Coverage. Geneva: World Health Organization, 2005.
21. Dowell F etal. Mortality from pneumonia ib children in the United States, 1939 through 1996. N Engl J Med 2000; 342: 1399-1407.
22. Swartz MN. Bacterial meningitis - a view of the past 90 years. N Engl J Med 2004; 351: 1826-1828.
23. Kellner J, Low D. Autimicrobial Resistance to Streptococcus pneumonia Infections: clinical and epidemiological trends. BMJ 1998; 4: 67-77.
24. Campagne A etal. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 1999; 77: 499-508.
25. Otten M etal. Hib-Paediatric Bacterial Meningitis (Hib-PBM) Surveillance Network. Surveillance Manual. Geneva: World Health Organization, 2001.
26. Lieu TA etal. Projected cost-effectiveness of Pneumococcal conjugate vaccination of healthy infants and young children. J Am Med Assoc 2000; 283: 1460-1468.
27. Pandey M etal. Reduction in total under-five mortality in western Nepal through community-based antimicrobial treatment of pneumonia. Lancet 1991; 1991: 993-997.
28. Tessa G etal. Outcome of meningitis caused by Streptococcus pneumonia and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 2000; 5: 207-213.
29. Murray CJL, Lopez AD, eds. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press, 1996: 412-418.
30. Global Alliance for Vaccines and Immunisation. Advanced Market Commitments for Vaccines: Pneumococcal AMC process sheet. 2009. (accessed 10 October 2009).
31. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development - Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001.
32. Pelton SI, Klein JO. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Pediatrics 2002; 110: 805-814.
33. Poehling KA etal. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295: 1668-1674.
34. Jackson LA etal. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-1755.
35. Cohen-Poradosu R, Kasper DL. Group a streptococcus epidemiology and vaccine implications. Clin Infect Dis 2007; 45: 863-865.
36. Munoz-Almagro C etal. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46: 174-182.
37. Rivera-Olivero IA etal. Pneumococcal carriage among indegenous warao children in venuzuela: serotypes, susceptibility pattersn, and molecular epidemiology. Clin Infect Dis 2007; 45: 1427-1434.
38. World Health Organization. World Health Statistics. Geneva: World Health Organization, 2006.
39. Sisk J etal. Cost-effectiveness of vaccination against pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138: 960-968.
40. Sinha A etal. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007; 369: 389-396.
41. Beutels P etal. Convincing or confusing? Economic evaluations of childhood Pneumococcal conjugate vaccination - a review (2002-2006). Vaccine 2007; 25: 1355-1367.
42. Chaiyakunapruk N etal. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med [online] 2011; 9: 53.
43. Global Alliance for Vaccines and Immunisation. Advance Market Commitments (AMCs). 2007. (accessed 20 February 2007).
44. PneuADIP. Surveillance and Research Report. Baltimore, MD: John Hopkins Bloomberg School of Public Health, John Hopkins University, 2007.